An interstitial deletion of the long arm of chromosome 5, del(5q), is a recurring abnormality in myeloid disorders, including myelodysplastic syndromes (MDS), acute myeloid leukemia de novo (AML), and therapy-related myeloid neoplasms (t-MN) comprising therapy-related MDS and AML (t-MDS/t-AML)
An interstitial deletion of the long arm of chromosome 5, del(5q), is a recurring abnormality in myeloid disorders, including myelodysplastic syndromes (MDS), acute myeloid leukemia de novo (AML), and therapy-related myeloid neoplasms (t-MN) comprising therapy-related MDS and AML (t-MDS/t-AML)
1
. In t-MN, a del(5q) occurs in ~40% of patients and is associated with prior therapy with alkylating agents, a complex karyotype, TP53 mutations, a strong propensity to progress to t-AML, and a poor outcome 2, 3 . We previously identified two haploinsufficient tumor suppressor genes on 5q, the early growth response gene, EGR1 (5q31.2, deleted in all t-MN with a del(5q)) and the adenomatous polyposis coli gene, APC (5q22.2, deleted in >95% of t-MNs with a del(5q)), and showed that heterozygous loss of Egr1 and Apc in mice promote the pathogenesis of MDS/AML, in cooperation with knockdown of Trp53 and/or alkylating agent therapy 4 . EGR1 is a member of the WT-1 family of transcription factors and is a transcriptional regulator of many tumor suppressor genes including TP53, CDKN1A/p21 and TGFB
5
. The APC protein acts as a tumor suppressor and is a negative regulator of the WNT signaling pathway 6 . Adding to the difficulty of identifying additional genes on 5q that may be contributing to the pathogenesis of MDS/AML, most patients have large deletions encompassing over 70 . The complex cytogenetic abnormalities and recurrent somatic mutations, such as ASXL1, NF1, TET2 and TP53 associated with advanced MDS and AML with a del(5q), has led to some insights; however, the complete genetic profile, and consequences thereof, are not yet known 3, 7 . Also, whether prior cytotoxic therapy induces mutations and/or promotes expansion of pre-existing genetic mutations in t-MNs is poorly understood. We used a mutagenesis approach in mice, heterozygous for Egr1 (Egr1 +/-), to identify genes and signaling pathways that predispose to developing del(5q) myeloid neoplasms (MNs). Figure 1B and supplemental Figure S1 ), and there was a significant increase in myeloid vs. no disease in Egr1 +/-mice (P < 0.001),
but not WT mice (P = 0.36) ( Figure 1C ) indicating that loss of one allele of Egr1 shifts the disease spectrum to favor the development of MNs. A Fisher Exact test indicated that the higher frequency of MNs observed in Egr1 +/-mice, compared to WT, trended towards significance (P=0.052). The morphological and phenotypic features of the diseases was similar in the Egr1 +/-and WT mice ( Figure 1D ).
We mapped the common retroviral integration sites (CISs) in MNs from WT and Egr1 +/-mice using barcoded splinkerette PCR and Illumina high-throughput sequencing.
TAPDANCE software, a fully automated process to identify and annotate CISs Figure 2A) . None of the genes implicated in cell growth and cancer within the common insertion sites (Gfi1, Ccdc21, Cd47, Cd52, Cxxc5, Evi5, Psd2, Tmem173 and Ubxn11) , displayed a significant change in expression in myeloid neoplasms due to retroviral integration (Supplemental Figure S2A ), except for Evi1
(Mecom: MDS1 and EVI1 complex locus), which showed a significant increase (Supplemental Figure S2B) . We showed that self-renewal of Evi1-expressing progenitors was enhanced by loss of Egr1 in vitro; however, there was no apparent cooperation between Evi1 overexpression and Egr1 haploinsufficiency leading to hematopoietic neoplasms using an in vivo mouse model (Supplemental Figure S2C , D).
Identifying which genes on 5q play a critical role in the development of MDS and AML continues to be a major challenge. Interestingly one CIS significantly associated with MNs in Egr1 +/-mice mapped to a region of mouse chromosome 18 that is syntenic to human 5q31.2 and proximal to the DNAJC18, ECSCR, TMEM173, CXXC5 and PSD2 genes ( Figure 2B ). Of relevance to MNs with a del(5q), this CIS co-occurred with a CIS on chromosome 13 (syntenic to 5q31.1 and proximal to the TIFAB, and H2AFY genes) (P = 0.001). In Gr1 + CD11b + myeloid bone marrow cells isolated from Egr1 +/-mice that had proviral integrations proximal to the 5q genes (CIS YES) versus mice that did not (CIS NO), Tifab expression was slightly higher and Cxxc5 lower, but not significantly, raising the possibility that aberrant expression of these genes may be important ( Figure 2C ). In leukemia samples from t-MN patients with a del(5q), CXXC5, TMEM173, TIFAB, and H2AFY showed ~50% lower expression relative to non-del(5q) samples, consistent with haploinsufficiency ( Figure 2D Figure 3B ).
LEF1 (Lymphoid Enhancer-Binding Factor 1) was also very highly expressed (2-15 fold)
in del(5q) t-MN patients (University of Chicago series 1 and 2) and del(5q) AML patients in the TCGA database, and we recently identified significant changes in the expression of Wnt pathway genes, consistent with activation, in del(5q) patients
EGR1, a transcriptional regulator expressed at haploinsufficient levels in del (5q) t-MN patients, is involved in the homeostasis of hematopoietic stem cells, in myeloid differentiation, and in neoplastic transformation 4, 14 . We hypothesize that dosage dependent deregulation of hematopoietic transcriptional programs contributes to the development of myeloid disease; however, the affected Egr1 targets genes are currently unknown. Interestingly, there was a significant enrichment of provirally-targeted genes that contain binding sites for at least one or more EGR family members (EGR1, EGR2, EGR3, EGR4) in WT, but not Egr1 +/-mice ( Figure 3C , Supplemental Table S3 , S4). Of these 40 potential EGR target genes, we identified 7 genes that were confirmed EGR1 targets by chromatin immunoprecipitation in K562 cells, and were differentially expressed in del(5q) vs. non del(5q) MNs. These include EGR1, ETF1 and ITPR1
(downregulated in del(5q) neoplasms) and BCL6, KLF3, LEF1and NRGN (upregulated in del(5q) neoplasms). These genes warrant consideration as potential EGR1 target genes that are deregulated during leukemogenesis in t-MN del(5q) patients. Notably, ETF1
(Eukaryotic Translation Termination Factor 1) has previously been suggested to act as a haploinsufficient tumor suppressor protein in MDS/AML patients with a del(5q), possibly through production of potentially oncogenic, aberrant proteins
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. In addition, ETF1 (5q31) and LEF1 (WNT target gene) expression may be deregulated in del(5q) patients due to EGR1 haploinsufficiency and/or loss of one copy of ETF1 and APC (5q22.2), respectively.
Patients with high risk MDS, AML or t-MN with a del(5q) present with a very complex genetic profile and have a poor response to current therapies and a poor prognosis. In this study, we used our previously described mouse model of t-MN, with loss of the critical del(5q) haploinsufficient myeloid tumor suppressor gene, EGR1.
Haploinsufficiency of Egr1, does not cause phenotypic abnormalities in mice under basal conditions; however, a reduction in Egr1 levels creates a sensitized background that cooperates with secondary mutations to give rise to myeloid malignancies. Moreover, our findings provide evidence that deregulation of genes at 5q31.1-5q31.2 (with TIFAB, CXXC5 and ETF1 being the most likely candidates) and activation of specific signaling pathways (with Wnt/β -catenin pathway the most likely aberrant pathway) are critical alterations that promote the development of MNs in cooperation with EGR1 haploinsufficiency. Notably, our studies also identify potential EGR1 target genes that may be deregulated during the progression towards t-MN (with ETF1 and LEF1 warranting further investigation).
Understanding the pathobiology of MN with a del(5q) has been challenging due to the large size of deletion and the ensuing haploinsufficient loss of multiple genes, and the additional genetic alterations that cooperate with 5q loss. This study is a step towards defining the critical pathways at play in MNs with a del(5q), which may inform the development of effective therapeutic strategies for this genetic subset of patients. Deregulation of these genes, possibly through EGR1 haploinsufficiency, may play an essential role in the malignant transformation process observed in patients with a del(5q).
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Of note, ETF1 maps to 5q31.2 immediately distal to EGR1 within the commonly deleted segment in MNs. 
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